

- c) a biologically active fragment comprising at least 15 contiguous amino acids of an amino acid sequence of SEQ ID NO:1, and
- d) an immunogenic fragment comprising at least 15 contiguous amino acids of an amino acid sequence of SEQ ID NO:1.

**11. (As Twice Amended.)** A composition comprising an effective amount of a polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

**12. (Reiterated.)** A purified antibody which binds specifically to a polypeptide of claim 1.

**13. (Reiterated.)** A purified agonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

**14. (Reiterated.)** A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

**15. (Reiterated.)** A pharmaceutical composition comprising an antagonist of claim 14 in conjunction with a suitable pharmaceutical carrier.

**16. (Reiterated.)** A method for treating liver disease comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition of claim 15.

**17. (Reiterated.)** A method for detection of a polynucleotide encoding a polypeptide comprising SEQ ID NO:1 in a biological sample, said method comprising the steps of:

- a) hybridizing an isolated and purified polynucleotide which is complementary to a polynucleotide encoding a polypeptide comprising SEQ ID NO:1 to nucleic acid material of a biological sample; and

b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding a polypeptide comprising SEQ ID NO:1 in said biological sample.

**18. (Reiterated.)** The method of claim 17, wherein before hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.

**19. (Reiterated.)** A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions; and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds the polypeptide of claim 1.

**20. (Reiterated.)** A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1; and

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound; and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a deviation between the activities is indicative of a compound that modulates the activity of the polypeptide of claim 1.

Please add the following new claims:

- **21. (New.)** A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

**22. (New.)** A composition comprising an effective amount of a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier. --